These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23343154)

  • 1. Conference report: 1st Medicon Valley Inhalation Symposium.
    Lastow O
    Ther Deliv; 2013 Feb; 4(2):149-51. PubMed ID: 23343154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conference report: 2nd Medicon Valley Inhalation Symposium.
    Lastow O
    Ther Deliv; 2014 Feb; 5(2):119-21. PubMed ID: 24483190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery Technologies for Orally Inhaled Products: an Update.
    Moon C; Smyth HDC; Watts AB; Williams RO
    AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally inhaled drug performance testing for product development, registration, and quality control.
    Lastow O; Svensson M
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):401-7. PubMed ID: 25237712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing drugs for local delivery.
    Collingwood S; Lock R; Searcey M
    Drug News Perspect; 2009 Dec; 22(10):627-34. PubMed ID: 20140283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements.
    Rangaraj N; Pailla SR; Sampathi S
    Pulm Pharmacol Ther; 2019 Feb; 54():1-21. PubMed ID: 30447295
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhalation devices and patient interface: human factors.
    Leiner S; Parkins D; Lastow O
    AAPS J; 2015 Mar; 17(2):457-61. PubMed ID: 25589457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing and advancing dry powder inhalation towards enhanced therapeutics.
    Stegemann S; Kopp S; Borchard G; Shah VP; Senel S; Dubey R; Urbanetz N; Cittero M; Schoubben A; Hippchen C; Cade D; Fuglsang A; Morais J; Borgström L; Farshi F; Seyfang KH; Hermann R; van de Putte A; Klebovich I; Hincal A
    Eur J Pharm Sci; 2013 Jan; 48(1-2):181-94. PubMed ID: 23142635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled Formulation Design for the Treatment of Lung Infections.
    Garcia-Contreras L; Yadav KS
    Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
    Olsson B; Borgström L; Lundbäck H; Svensson M
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhalation: past, present and future.
    de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
    Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closer to an 'ideal inhaler' with the Easyhaler: an innovative dry powder inhaler.
    Chrystyn H
    Clin Drug Investig; 2006; 26(4):175-83. PubMed ID: 17163249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in inhaled product development and opportunities for open innovation.
    Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
    Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deposition, imaging, and clearance: what remains to be done?
    Scheuch G; Bennett W; Borgström L; Clark A; Dalby R; Dolovich M; Fleming J; Gehr P; Gonda I; O'Callaghan C; Taylor G; Newman S
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S39-57. PubMed ID: 21133799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.